script.reportAU
Haematology

Ibrutinib

Brand: Imbruvica

PBAC's latest decision on Ibrutinib: Recommended with restriction (2024). Considered for Previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL), in combination with venetoclax, for patients suitable for fludarabine-based chemoimmunotherapy.

PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
12
first 2015
PBS spend
$82M
9,692 scripts · 2024

Eligible population

Adults with previously untreated CLL/SLL who would otherwise be considered fit for treatment with fludarabine-based chemoimmunotherapy; receiving fixed duration ibrutinib (420 mg daily for 3 cycles lead-in, then continued with venetoclax for 12 further cycles) in combination with venetoclax.

Therapy area
Haematology
Line of therapy
First-line
Evidence base
RCT
Primary endpoint
PFS
Key trials
CAPTIVATE, GLOW, CLL-14
Comparator
venetoclax + obinutuzumab
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis performed; no ICER calculated by design.
ICER (historical)
$45k/QALY–$75k/QALY across 4 submissions (2015–2018) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.

PBS expenditure

The Australian government paid $82M in PBS benefits for Ibrutinib in 2024 across 9,692 scripts, at $8,454 per script.

Submission history

Similar precedents

Open on full dashboard →